]>

Table 4: Review of multikinase inhibitors that have been studied in ovarian cancer. RR: response rate, SD: stable disease, HTN: hypertension, HFS: hand-foot syndrome.

Agent(s) Authors RR SD Toxicities Sorafenib Matei et al. 2/59 partial 20/59 Rash, GI, cardiovascular, metabolic, pulmonary Sorafenib + bevacizumab Azad et al. 6/13 partial HTN, diarrhea, HFS, thrombocytopenia, proteinuria, fistula Sorafenib + gemcitabine Welch et al. 6/18 partial 10/18 Lymphopenia, thrombocytopenia, HTN, HFS, pain, neutropenia, hypokalemia Imatinib Coleman et al. 0/12 4/12 Fatigue, nausea/vomiting, rash, neutropenia Imatinib Alberts et al. 0/19 Hematologic, metabolic Imatinib Schilder et al. 1/56 complete Neutropenia, GI, dermatologic, pain, electrolyte disturbances